Patient-derived organoids are emerging as powerful tools for translational research, offering physiologically relevant models that better reflect human biology than traditional in vitro systems. Their ability to preserve key characteristics of patient tissues presents new opportunities for disease modeling, target validation, biomarker discovery, and therapeutic evaluation. This webinar explores the growing role of organoid technologies in drug development and discuss how patient-derived organoid platforms can support more informed decision-making throughout the process. Drawing on recent experience and case examples, the session will highlight practical applications, current challenges, and future opportunities for integrating organoids into translational research.
Speakers
Samsung Biologics
Dr. Alexis Santana is a Business Development Director at Samsung Biologics, supporting commercialization of the company’s patient-derived organoid (PDO) platform. With expertise spanning oncology research, translational medicine, and biopharma partnerships, she works with organizations across the life sciences industry to evaluate advanced preclinical models for drug discovery and development. Dr. Santana holds a PhD in Molecular Genetics and Microbiology and an Executive MBA.
